Device_News
27 April 2021

Microbix & SpeeDx Form Exclusive Collaboration

Partnerships, Press releases

Microbix Biosystems Inc. (TSX: MBX. OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, and SpeeDx Pty. Ltd. announced a collaboration where Microbix will exclusively develop Quality Assessment Products to facilitate the registration and commercialization of SpeeDx diagnostic assays.
The new generation of diagnostics being developed by SpeeDx detect the mutations that drive resistance, enabling more effective treatment. In turn, Microbix has established how to create QAPs for antimicrobial-resistant (AMR) or extremely drug-resistant (XDR) versions of bacteria and viruses – safely, economically, and in large quantities.
Colin Denver, CEO of SpeeDx, commented, “it  makes great sense to work with Microbix and apply its innovative and proprietary controls to ensure the best-possible accuracy of our tests.”

Read the full press release

Print page